Status:
COMPLETED
To Evaluate the Pharmacokinetic Interactions and Safety in Healthy Volunteers
Lead Sponsor:
JW Pharmaceutical
Conditions:
Healthy
Eligibility:
All Genders
19-45 years
Phase:
PHASE1
Brief Summary
To evaluate and compare the pharmacokinetic interactions and safety of multiple dose of Treatment A and Treatment B alone and in combination
Detailed Description
The objective of this study was to evaluate pharmacokinetic characteristics and safety after oral concurrent administration of Treatment A and Treatment B compared to each single administration in Hea...
Eligibility Criteria
Inclusion
- Healthy volunteers, aged between 19 to 45 years (both inclusive) at the screening.
- Subjects who are informed of the investigational nature of this study, and voluntarily agree to participate in this study and signs informed consent
Exclusion
- Subjects who have a clinically significant past or present medical history of hepato-biliary, renal, gastrointestinal, respiratory, hematologic/neoplastic, endocrine, urologic, psychiatric, musculoskeletal, immunologic, Otorhinolaryngological, and cardiovascular diseases.
- Subjects who have a medical history and/or condition that is considered to be dangerous to take the study drug.
Key Trial Info
Start Date :
November 2 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 15 2021
Estimated Enrollment :
31 Patients enrolled
Trial Details
Trial ID
NCT05351840
Start Date
November 2 2020
End Date
January 15 2021
Last Update
August 12 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinical Trial Center, Chungnam National University Hospital
Daejeon, South Korea